Teratocarcinoma-Derived Growth Factor-1 (TDGF-1): A Guide Molecule for Monitoring the Treatment Success of Iraqi Patients with Colorectal Carcinoma

This study was carried out in Al Ramadi Teaching hospital from the period March 2013 till August 2013 on sixty two (62) Iraqi patients with colorectal carcinoma. Their ages range from 8–47 years old complain from disturbances in GIT. All patients were visiting the department of surgery in Al-Ramadi teaching hospital. Five ml venous blood was withdrawn from the patients and placed into a plain test tube without anticoagulant to obtain sera. The blood samples were taken from the patients before and after receiving adjuvant chemotherapy and from the healthy individuals (control group 2). The results obtained regarding estimation of TDGF-1 levels in colorectal carcinoma patients revealed that there is a higher significant difference in their concentrations before treatment (3.0 ng/ml) and after chemotherapy treatment (1.2 ng/ml). TDGF-1 level in control group 2 was (0.1 ng/ml). that means, the expression of this TDGF-1 marker in cancerous patients was higher compared with low in normal tissues make it is the target of chemotherapy so evaluation of this marker during receiving chemotherapy give an effective results to choose the best mode of treatment and exclude the non effective ones.